Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study

Figure 3

Maximum change from baseline in the sum of the longest diameters of target lesions (as assessed by the investigator per RECIST). "Unevaluable" refers to patients who had a response assessment before the scheduled first assessment without an additional postbaseline assessment. 1 = 50 mg QD + gemcitabine/erlotinib; 2 = 75 mg BID + gemcitabine/erlotinib; 3 = 125 mg QD + gemcitabine/erlotinib; 4 = 100 mg QD + gemcitabine/erlotinib; 5 = 100 mg QD + erlotinib; 6 = 125 mg QD + erlotinib.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us